(-) -DHMEQ

(-) -DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-) -DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity[1][2][3].

Product Specifications

CAS Number

[287194-40-5]

Product Name Alternative

Dehydroxymethylepoxyquinomicin

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/_-_-DHMEQ.html

Purity

99.81

Solubility

DMSO : 95 mg/mL (ultrasonic)

Smiles

O=C1[C@@H](O2)[C@@H]2[C@@H](O)C(NC(C3=C(O)C=CC=C3)=O)=C1

Molecular Formula

C13H11NO5

Molecular Weight

261.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40 (10) :1669-1677.|[2]Yinzhi Lin, et al. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.|[3]Mariko Watanabe, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106 (7) :2462-71.